Overexpression of glycogen synthase kinase-3 in ovarian carcinoma cells with acquired paclitaxel resistance

International Journal of Gynecological Cancer

Volumn 21, Issue 3, 2011, Pages 439-444

  Fu, Yunfeng ^a   Hu, Dongxiao ^a   Qiu, Jian ^a   Xie, Xing ^a,b   Ye, Feng ^b   Lu, Wei Guo ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Women's Reproductive and Health Laboratory of Zhejiang Province   (China)

Author keywords

Drug resistance; Gene expression; Glycogen synthase kinase 3; Ovarian carcinoma; Paclitaxel

Indexed keywords

COMPLEMENTARY DNA; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3ALPHA; MESSENGER RNA; PACLITAXEL; ANTINEOPLASTIC AGENT; GLYCOGEN SYNTHASE KINASE 3 ALPHA; GLYCOGEN SYNTHASE KINASE 3 BETA; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; FLOW CYTOMETRY; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; OVARY TUMOR; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CELL CYCLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GLYCOGEN SYNTHASE KINASE 3; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PACLITAXEL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 80051652238     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31820d7366     Document Type: Article

References (23)

1. Guarneri V, Piacentini F, Barbieri E, et al. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol. 2010;117:152-158.
2. Park MT, Lee SJ. Cell cycle and cancer. J Biochem Mol Biol. 2003;36:60-65.
3. Kohn KW, Jackman J, O'Connor PM. Cell cycle control and cancer chemotherapy. J Cell Biochem. 1994;54:440-452. (Pubitemid 24131349)
4. Rayasam GV, Tulasi VK, Sodhi R, et al. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol. 2009;156:885-898.
5. Ryves WJ, Harwood AJ. The interaction of glycogen synthase kinase-3 (GSK-3) with the cell cycle. Prog Cell Cycle Res. 2003;5:489-495.
6. Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett. 2009;273:194-200.
7. Patel S, Woodgett J. Glycogen synthase kinase-3 and cancer: good cop, bad cop? Cancer Cell. 2008;14:351-353.
8. Fu Y, Ye D, Chen H, et al. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30. Gynecol Oncol. 2007;105:66-73. (Pubitemid 46441441)
9. G-Amlak M, Uddin S, Mahmud D, et al. Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. Biochem Biophys Res Commun. 2002;297:760-764. (Pubitemid 35230315)
10. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, et al. Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 2005;65:2076-2081. (Pubitemid 40490111)
11. Liao X, Zhang L, Thrasher JB, et al. Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther. 2003;2:1215-1222.
12. Shakoori A, Ougolkov A, Yu ZW, et al. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun. 2005;334:1365-1373. (Pubitemid 41074725)
13. Rottmann S, Wang Y, Nasoff M, et al. A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function. Proc Natl Acad Sci U S A. 2005;102:15195-15200. (Pubitemid 41513358)
14. Cao Q, Lu X, Feng YJ. Glycogen synthase kinase-3β positively regulates the proliferation of human ovarian cancer cells. Cell Research. 2006;16:671-677. (Pubitemid 44091443)
15. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, et al. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther. 2007;6:1151-1158. (Pubitemid 46554586)
16. Ougolkov AV, Bone ND, Fernandez-Zapico ME, et al. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood. 2007;110:735-742. (Pubitemid 47105412)
17. Kotliarova S, Pastorino S, Kovell LC, et al. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res. 2008;68:6643-6651.
18. Beurel E, Kornprobst M, Blivet-Van Eggelpoël MJ, et al. GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression. Exp Cell Res. 2004;300:354-364. (Pubitemid 39314425)
19. Beurel E, Kornprobst M, Blivet-Van Eggelpoël MJ, et al. GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis. Int J Oncol. 2005;27:215-222.
20. Cai G, Wang J, Xin X, et al. Phosphorylation of glycogen synthase kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells. Int J Oncol. 2007;31:657-662.
21. Alao JP, Stavropoulou AV, Lam EW, et al. Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells. Mol Cancer. 2006;5:40.
22. Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol. 2006;79:173-189. (Pubitemid 44331500)
23. Takahashi-Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal. 2008;20:581-589. (Pubitemid 351241128)